ClinicalTrials.gg
CompletedNCT00474630Updated Nov 21, 2014Results posted

A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes

A Phase 3 interventional study of Naltrexone SR 32 mg/bupropion SR 360 mg/ day and Placebo in Obesity, Overweight and Diabetes Mellitus, Type 2, sponsored by Orexigen Therapeutics, Inc. Completed at 53 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-11-21.

Sponsored by Orexigen Therapeutics, Inc · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
505
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing naltrexone in Obesity — 4 open to participants now, 4 under way, none of them phase 3. Naltrexone · Obesity.

Enrollment
5th of 23
505 · median 67
Started
2007
with 4 others
Phase 3
6 of 23
none open now
Registered
3rd of 23
by date
Lead sponsor
10 of 23
Orexigen Therapeutics, Inc

Among the 23 studies testing naltrexone in Obesity, this one is the 5th largest by enrollment, is one of 5 that started in 2007, is one of 6 in phase 3, and was the 3rd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 23 studies testing naltrexone in Obesity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About naltrexone

Naltrexone: first FDA approval 1984 (REVIA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing naltrexone in Obesity, or all of them as a file.
02

Study summary

The purpose of this study is determine whether the combination of naltrexone SR and bupropion SR is safe and effective in treating obesity in subjects with type 2 diabetes.

Read the detailed description

Optimal care of patients with diabetes mellitus includes vigorous and persistent efforts to achieve physiologic control of blood glucose as well as other often associated conditions including hypertension, dyslipidemia and excess weight. Pharmacologic interventions for the treatment of obesity in type 2 diabetes have shown significant reductions in HbA1c. Two Phase II clinical trials demonstrated that a combination of bupropion SR and naltrexone is associated with greater weight loss than bupropion SR alone, naltrexone alone, or placebo in subjects with uncomplicated obesity. The current study investigated the safety and efficacy of the combination of naltrexone SR and bupropion SR compared to placebo in obese subjects with type 2 diabetes mellitus.

03

Conditions studied

  • Obesity
  • Overweight
  • Diabetes Mellitus, Type 2

Keywords

  • Obesity
  • Overweight
  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female or male subjects aged 18 to 70 years of age (inclusive)
  • (BMI) ≥27 and ≤45 kg/m²
  • Diagnosed with type 2 diabetes mellitus and on no injectable antidiabetes medication or inhaled insulin for more than 3 months prior to randomization
  • Took stable doses of oral single or combination hypoglycemic medications (biguanides, thiazolidinediones, meglitinides, α-glucosidase inhibitors, sulfonylureas, DPP4 inhibitors) for at least 3 months prior to randomization or did not take medications for the treatment of type 2 diabetes mellitus
  • Normotensive (systolic ≤145 mm Hg and diastolic ≤95 mm Hg). Antihypertensive medications were allowed with the exception of alpha-adrenergic blockers, and clonidine. Antihypertensive treatment was stable for at least 4 weeks prior to randomization.
  • Medications for the treatment of dyslipidemia were allowed with the exception of cholestyramine and cholestypol as long as the medical regimen had been stable for at least 4 weeks prior to randomization.
  • Free of opioid medication for 7 days prior to randomization
  • between 7% and 10%, fasting blood glucose \<270 mg/dL, and fasting triglycerides \<400 mg/dL
  • No abnormality of serum albumin, blood urea nitrogen (BUN), , calcium, and phosphorus
  • Creatinine levels were ≤1.4 mg/dL for female subjects and ≤1.5 mg/dL for male subjects
  • (ALT) and aspartate aminotransferase (AST) levels were within 2.5 × upper limit of laboratory normal range ()
  • No clinically significant abnormality of hematocrit, white blood cell (WBC) count, WBC differential, or
  • No clinically significant abnormality on urinalysis
  • TSH within normal limits or normal T3, if TSH is below normal limits
  • Female subjects of had a negative serum pregnancy test
  • Negative urine drug screen
  • An IDS-SR score \<2 on individual items 5 (sadness), 6 (irritability), 7 (anxiety/tension), and 18 (suicidality) and an IDS-SR total score \<30
  • Female subjects of childbearing potential were non-lactating and agreed to continue to use effective throughout the study and 30 days after discontinuation of study drug
  • Able to comply with all required study procedures and schedule
  • Able to speak and read English
  • Provided written

Exclusion criteria

Exclusion Criteria:

  • Type I diabetes mellitus
  • "Brittle-diabetes" or any hospitalization or emergency room visit due to poor diabetic control within 6 months prior to screening, history of diabetes-related dehydration leading to hospitalization, or history or evidence of ketoacidosis
  • Obesity of known endocrine origin other than diabetes mellitus (e.g., untreated hypothyroidism, Cushing's syndrome, established polycystic ovary syndrome)
  • Diabetes mellitus secondary to pancreatitis or pancreatectomy
  • Serious medical condition including but not limited to renal or hepatic insufficiency and Class III or IV congestive heart failure; history of myocardial infarction, angina pectoris, claudication, or acute limb ischemia within 6 months prior to screening; lifetime history of stroke
  • History of with exception of non-melanoma skin cancer or surgically cured cervical cancer within 5 years prior to screening
  • Loss or gain of more than 5.0 kg within the 3 months prior to screening
  • Severe microvascular or macrovascular complications of diabetes, including but not limited to proliferative retinopathy, active limb ulcerations, amputation of metatarsals or above
  • Serious psychiatric illness, including lifetime history of bipolar disorder, schizophrenia or other psychosis, bulimia, and anorexia nervosa; current serious personality disorder (e.g., borderline or antisocial); current severe major depressive disorder; recent (6 months prior to screening) suicide attempt or current active suicidal ideation; or recent hospitalization due to psychiatric illness
  • Response to the bipolar disorder questions that indicated the presence of bipolar disorder
  • Required medications for the treatment of a psychiatric disorder (with the exception of short term insomnia) within 6 months prior to screening
  • History of drug or alcohol abuse or dependence within 1 year prior to screening
  • Baseline with a (Bazett's formula) >450 msec (men) and >470 msec (women) or the presence of any cardiac abnormalities, including but not limited to patterns consistent with recent myocardial ischemia, electrolyte abnormalities, or atrial or ventricular dysrhythmia or significant conduction abnormalities
  • Received the following excluded concomitant medications: any psychotropic agents (including antipsychotic, antidepressant, anxiolytic, mood stabilizer, anticonvulsant agents, and agents for the treatment of attention deficit disorder) with the exception of low-dose benzodiazepine or hypnotic agents for the treatment of insomnia (up to 2 mg lorazepam/day or equivalent dose of a benzodiazepine or hypnotic agent); any anorectic or weight loss agents; any over-the-counter dietary supplements or herbs with psychoactive, appetite, or weight effects; alpha-adrenergic blockers; dopamine agonists; clonidine; coumadin; theophylline; cimetidine; oral ; cholestyramine, cholestypol, Depo Provera®; smoking cessation agents; use of opioid or opioid-like medications, including analgesics and antitussives
  • History of surgical or device intervention for obesity (e.g., gastric banding)
  • History of seizures of any etiology, or of predisposition to seizures (e.g., history of cerebrovascular accident, head trauma with ≥5 minutes loss of consciousness, concussion symptoms lasting ≥15 minutes, brain surgery, skull fracture, subdural hematoma, or febrile seizures)
  • Treatment with bupropion or naltrexone within 12 months prior to screening
  • History of or intolerance to bupropion or naltrexone
  • Changes in smoking status or in tobacco or nicotine use within 3 months prior to screening or planned during study participation
  • Participated in a weight loss management program within one month prior to randomization
  • Females who were pregnant or breast-feeding or planned to become pregnant during the study period or within 30 days of discontinuing study drug
  • Planned surgical procedure that could impact the conduct of the study
  • Received any drug or used an experimental device or procedure within the previous 30 days
  • Participated in any previous clinical trial conducted by Orexigen
  • Had any condition that in the opinion of the investigator made the subject unsuitable for inclusion into the study
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
505 participants (actual)

Study arms

  • Experimental
    NB32

    Naltrexone SR 32 mg/bupropion SR 360 mg/ day with ancillary therapy

    Drug: Naltrexone SR 32 mg/bupropion SR 360 mg/ day · Behavioral: Ancillary therapy

  • Placebo comparator
    Placebo

    Placebo with ancillary therapy

    Drug: Placebo · Behavioral: Ancillary therapy

Interventions

  • DrugNaltrexone SR 32 mg/bupropion SR 360 mg/ day

    Drug page: Naltrexone

    Also known as: NB32

  • DrugPlacebo
  • BehavioralAncillary therapy

    Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling

06

What researchers measure

Primary outcomes

  1. Co-primary: Body Weight- Mean Percent Change

    Time frame: Baseline, 56 weeks

  2. Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease

    Time frame: Baseline, 56 weeks

Secondary outcomes

  1. Change in HbA1c Levels

    Time frame: Baseline, 56 weeks

  2. Change in Fasting Triglycerides Levels, Using Log-transformed Data

    Time frame: Baseline, 56 weeks

  3. Change in Fasting HDL Cholesterol Levels

    Time frame: Baseline, 56 weeks

  4. Change in Fasting Blood Glucose Levels

    Time frame: Baseline, 56 weeks

  5. Change in Waist Circumference

    Time frame: Baseline, 56 weeks

  6. Body Weight- Proportion of Subjects With ≥10% Decrease

    Time frame: Baseline, 56 weeks

  7. HbA1c- Proportion of Subjects With HbA1c <7% at Endpoint

    Time frame: Baseline, 56 weeks

  8. Percent of Subjects Requiring Rescue Medications for Diabetes

    Time frame: Baseline, 56 weeks

  9. Percent of Subjects With Dose Reduction in Oral Antidiabetes Medications

    Time frame: Baseline, 56 weeks

  10. Percent of Subjects With Dose Increase in Oral Antidiabetes Medications

    Time frame: Baseline, 56 weeks

  11. Change in HOMA-IR Levels, Using Log-transformed Data

    HOMA-IR= Homeostasis Model Assessment-Insulin Resistance

    Time frame: Baseline, 56 weeks

  12. Change in Fasting Insulin Levels, Using Log-transformed Data

    Time frame: Baseline, 56 weeks

  13. HbA1c- Proportion of Subjects With HbA1c <6.5% at Endpoint

    Time frame: Baseline, 56 weeks

  14. Change in IWQOL-Lite Total Scores

    IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment

    Time frame: Baseline, 56 weeks

  15. Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data

    Time frame: Baseline, 56 weeks

  16. Percent of Subjects Discontinuing Due to Poor Glycemic Control

    Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed. Odds ratio not calculated as there were no subjects in the NB32 group that discontinued due to poor glycemic control.

    Time frame: Baseline, 56 weeks

  17. Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire

    Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult

    Time frame: Baseline, 56 weeks

  18. Change in Fasting LDL Cholesterol Levels

    Time frame: Baseline, 56 weeks

  19. Change in Systolic Blood Pressure

    Time frame: Baseline, 56 weeks

  20. Change in Diastolic Blood Pressure

    Time frame: Baseline, 56 weeks

  21. Change in IDS-SR Total Scores

    IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression.

    Time frame: Baseline, 56 weeks

  22. Change in Food Craving Inventory Sweets Subscale Score

    The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).

    Time frame: Baseline, 56 weeks

  23. Change in Food Craving Inventory Carbohydrates Subscale Score

    The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).

    Time frame: Baseline, 56 weeks

07

Results

Posted Nov 21, 2014

Participant flow

Participant flow — Overall Study
MilestoneNB32Placebo
Started335170
Completed175100
Not completed16070
Withdrew: Adverse event9826
Withdrew: Lost to follow-up2215
Withdrew: Withdrawal by subject2115
Withdrew: Protocol violation34
Withdrew: Lack of efficacy56
Withdrew: Drug noncompliance, other114

Outcome measures

PrimaryCo-primary: Body Weight- Mean Percent Change
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · percentage of body weight
Co-primary: Body Weight- Mean Percent Change
percentage of body weightNB32Placebo
Co-primary: Body Weight- Mean Percent Change-5.03 ± 0.34-1.75 ± 0.43
Statistical analysis
  • NB32 vs Placebo · ANCOVA · p = <0.001 · Mean difference (net): -3.28 · 95% CI -4.34 to -2.22
SecondaryChange in HbA1c Levels
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · percent
Change in HbA1c Levels
percentNB32Placebo
Change in HbA1c Levels-0.63 ± 0.07-0.14 ± 0.09
Statistical analysis
  • NB32 vs Placebo · ANCOVA · p = <0.001 · Mean difference (net): -0.49 · 95% CI -0.71 to -0.27
PrimaryCo-primary: Body Weight- Proportion of Subjects With ≥5% Decrease
Time frame:
Baseline, 56 weeks
Reported as:
Number · percentage of participants
Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease
percentage of participantsNB32Placebo
Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease44.53 (38.54 to 50.51)18.87 (12.79 to 24.95)
Statistical analysis
  • NB32 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.44 · 95% CI 2.15 to 5.50
SecondaryChange in Fasting Triglycerides Levels, Using Log-transformed Data
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · percent change
Change in Fasting Triglycerides Levels, Using Log-transformed Data
percent changeNB32Placebo
Change in Fasting Triglycerides Levels, Using Log-transformed Data-11.20 (-15.59 to -6.58)-0.80 (-6.95 to 5.76)
Statistical analysis
  • NB32 vs Placebo · ANCOVA · p = 0.007 · Mean difference (net): -10.4
SecondaryChange in Fasting HDL Cholesterol Levels
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · mg/dL
Change in Fasting HDL Cholesterol Levels
mg/dLNB32Placebo
Change in Fasting HDL Cholesterol Levels3.03 ± 0.49-0.29 ± 0.61
Statistical analysis
  • NB32 vs Placebo · ANCOVA · p = <0.001 · Mean difference (net): 3.32 · 95% CI 1.80 to 4.84
SecondaryChange in Fasting Blood Glucose Levels
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · mg/dL
Change in Fasting Blood Glucose Levels
mg/dLNB32Placebo
Change in Fasting Blood Glucose Levels-11.87 ± 2.70-4.02 ± 3.39
Statistical analysis
  • NB32 vs Placebo · ANCOVA · p = 0.065 · Mean difference (net): -7.85 · 95% CI -16.21 to 0.50
SecondaryChange in Waist Circumference
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · cm
Change in Waist Circumference
cmNB32Placebo
Change in Waist Circumference-4.97 ± 0.47-2.89 ± 0.61
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): -2.08 · 95% CI -3.57 to -0.59
SecondaryBody Weight- Proportion of Subjects With ≥10% Decrease
Time frame:
Baseline, 56 weeks
Reported as:
Number · percentage of participants
Body Weight- Proportion of Subjects With ≥10% Decrease
percentage of participantsNB32Placebo
Body Weight- Proportion of Subjects With ≥10% Decrease18.49 (13.82 to 23.16)5.66 (2.07 to 9.25)
Statistical analysis
  • NB32 vs Placebo · Odds ratio (or): 3.75 · 95% CI 1.79 to 7.88
SecondaryHbA1c- Proportion of Subjects With HbA1c <7% at Endpoint
Time frame:
Baseline, 56 weeks
Reported as:
Number · percentage of participants
HbA1c- Proportion of Subjects With HbA1c <7% at Endpoint
percentage of participantsNB32Placebo
HbA1c- Proportion of Subjects With HbA1c <7% at Endpoint44.14 (37.61 to 50.68)26.28 (18.91 to 33.65)
Statistical analysis
  • NB32 vs Placebo · Odds ratio (or): 2.46 · 95% CI 1.50 to 4.04
SecondaryPercent of Subjects Requiring Rescue Medications for Diabetes
Time frame:
Baseline, 56 weeks
Reported as:
Number · percentage of participants
Percent of Subjects Requiring Rescue Medications for Diabetes
percentage of participantsNB32Placebo
Percent of Subjects Requiring Rescue Medications for Diabetes22.26 (19.05 to 29.91)35.22 (29.81 to 45.36)
Statistical analysis
  • NB32 vs Placebo · Odds ratio (or): 0.55 · 95% CI 0.35 to 0.86
SecondaryPercent of Subjects With Dose Reduction in Oral Antidiabetes Medications
Time frame:
Baseline, 56 weeks
Reported as:
Number · percentage of participants
Percent of Subjects With Dose Reduction in Oral Antidiabetes Medications
percentage of participantsNB32Placebo
Percent of Subjects With Dose Reduction in Oral Antidiabetes Medications1.89 (0.28 to 3.87)1.26 (0.00 to 3.19)
Statistical analysis
  • NB32 vs Placebo · Odds ratio (or): 1.43 · 95% CI 0.27 to 7.57
SecondaryPercent of Subjects With Dose Increase in Oral Antidiabetes Medications
Time frame:
Baseline, 56 weeks
Reported as:
Number · percentage of participants
Percent of Subjects With Dose Increase in Oral Antidiabetes Medications
percentage of participantsNB32Placebo
Percent of Subjects With Dose Increase in Oral Antidiabetes Medications3.02 (1.06 to 5.58)1.26 (0.00 to 3.19)
Statistical analysis
  • NB32 vs Placebo · Odds ratio (or): 2.63 · 95% CI 0.55 to 12.67
SecondaryChange in HOMA-IR Levels, Using Log-transformed Data

HOMA-IR= Homeostasis Model Assessment-Insulin Resistance

Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · percent change
Change in HOMA-IR Levels, Using Log-transformed Data
percent changeNB32Placebo
Change in HOMA-IR Levels, Using Log-transformed Data-20.56 (-27.77 to -12.62)-14.67 (-24.69 to -3.31)
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): -5.89
SecondaryChange in Fasting Insulin Levels, Using Log-transformed Data
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · percent change
Change in Fasting Insulin Levels, Using Log-transformed Data
percent changeNB32Placebo
Change in Fasting Insulin Levels, Using Log-transformed Data-13.48 (-19.70 to -6.78)-10.35 (-18.75 to -1.09)
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): -3.13
SecondaryHbA1c- Proportion of Subjects With HbA1c <6.5% at Endpoint
Time frame:
Baseline, 56 weeks
Reported as:
Number · percentage of participants
HbA1c- Proportion of Subjects With HbA1c <6.5% at Endpoint
percentage of participantsNB32Placebo
HbA1c- Proportion of Subjects With HbA1c <6.5% at Endpoint20.72 (15.39 to 26.05)10.22 (5.15 to 15.29)
Statistical analysis
  • NB32 vs Placebo · Odds ratio (or): 2.64 · 95% CI 1.36 to 5.14
SecondaryChange in IWQOL-Lite Total Scores

IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment

Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · units on a scale
Change in IWQOL-Lite Total Scores
units on a scaleNB32Placebo
Change in IWQOL-Lite Total Scores9.27 ± 0.707.90 ± 0.86
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): 1.37 · 95% CI -0.77 to 3.51
SecondaryChange in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · percent change
Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data
percent changeNB32Placebo
Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data-20.91 (-29.29 to -11.54)-13.29 (-24.94 to 0.17)
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): -7.62
SecondaryPercent of Subjects Discontinuing Due to Poor Glycemic Control

Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed. Odds ratio not calculated as there were no subjects in the NB32 group that discontinued due to poor glycemic control.

Time frame:
Baseline, 56 weeks
Reported as:
Number · percentage of participants
Percent of Subjects Discontinuing Due to Poor Glycemic Control
percentage of participantsNB32Placebo
Percent of Subjects Discontinuing Due to Poor Glycemic Control0 (NA to NA)1.89 (0.00 to 4.00)
SecondaryChange in Question 19 From 21-Item COE (Control of Eating) Questionnaire

Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult

Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · units on a scale
Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire
units on a scaleNB32Placebo
Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire-11.89 ± 1.39-6.91 ± 1.69
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): -4.98 · 95% CI -9.22 to -0.74
SecondaryChange in Fasting LDL Cholesterol Levels
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · mg/dL
Change in Fasting LDL Cholesterol Levels
mg/dLNB32Placebo
Change in Fasting LDL Cholesterol Levels-1.44 ± 1.94-0.01 ± 2.44
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): -1.43 · 95% CI -7.48 to 4.62
SecondaryChange in Systolic Blood Pressure
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · mm Hg
Change in Systolic Blood Pressure
mm HgNB32Placebo
Change in Systolic Blood Pressure0.03 ± 0.70-1.12 ± 0.88
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): 1.16 · 95% CI -1.02 to 3.33
SecondaryChange in Diastolic Blood Pressure
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · mm Hg
Change in Diastolic Blood Pressure
mm HgNB32Placebo
Change in Diastolic Blood Pressure-1.06 ± 0.47-1.47 ± 0.59
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): 0.41 · 95% CI -1.04 to 1.86
SecondaryChange in IDS-SR Total Scores

IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression.

Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · units on a scale
Change in IDS-SR Total Scores
units on a scaleNB32Placebo
Change in IDS-SR Total Scores0.01 ± 0.33-1.60 ± 0.42
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): 1.62 · 95% CI 0.59 to 2.65
SecondaryChange in Food Craving Inventory Sweets Subscale Score

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).

Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · units on a scale
Change in Food Craving Inventory Sweets Subscale Score
units on a scaleNB32Placebo
Change in Food Craving Inventory Sweets Subscale Score-1.97 ± 0.28-2.40 ± 0.34
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): 0.43 · 95% CI -0.42 to 1.27
SecondaryChange in Food Craving Inventory Carbohydrates Subscale Score

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).

Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · units on a scale
Change in Food Craving Inventory Carbohydrates Subscale Score
units on a scaleNB32Placebo
Change in Food Craving Inventory Carbohydrates Subscale Score-1.48 ± 0.26-1.52 ± 0.32
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): 0.04 · 96% CI -0.76 to 0.85

Adverse events

Collected over Baseline, 56 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NB32—13/333 (3.9%)275/333 (82.6%)
Placebo—8/169 (4.7%)109/169 (64.5%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventNB32Placebo
Angina pectorisCardiac disorders0/3332/169
Atrial fibrillationCardiac disorders0/3332/169
Syncope vasovagalNervous system disorders2/3330/169
ArrhythmiaCardiac disorders0/3331/169
Anaphylactic reactionImmune system disorders0/3331/169
CellulitisInfections and infestations1/3331/169
Staphylococcal infectionInfections and infestations0/3331/169
Troponin increasedInvestigations0/3331/169
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3331/169
Cerebrovascular accidentNervous system disorders0/3331/169
Most frequent other events
Showing 10 of 21
Most frequent other events
EventNB32Placebo
NauseaGastrointestinal disorders141/33312/169
VomitingGastrointestinal disorders61/3336/169
ConstipationGastrointestinal disorders59/33312/169
DiarrhoeaGastrointestinal disorders52/33316/169
HeadacheNervous system disorders46/33315/169
NasopharyngitisInfections and infestations28/33323/169
DizzinessNervous system disorders39/3339/169
InsomniaPsychiatric disorders37/3339/169
HypertensionVascular disorders33/3337/169
Upper respiratory tract infectionInfections and infestations26/33316/169

Baseline characteristics

All randomized subjects

Age, Continuous
Age, Continuous(years)NB32PlaceboTotal
Mean54.02 ± 9.0553.46 ± 9.8353.83 ± 9.32
Sex: Female, Male
Sex: Female, Male(Participants)NB32PlaceboTotal
Female19590285
Male14080220
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)NB32PlaceboTotal
White261140401
Black or African American631881
Asian7512
Native Hawaiian or Other Pacific Islander101
American Indian or Alaska Native224
Other156
Weight
Weight(kg)NB32PlaceboTotal
Mean104.22 ± 18.93105.08 ± 16.99104.51 ± 18.28
BMI
BMI(kg/m^2)NB32PlaceboTotal
Mean36.40 ± 4.7536.40 ± 4.5036.40 ± 4.66
08

Study locations

53 sites
  • SelfCenter, PC
    Fairhope, Alabama 36532, United States
  • Pivotal Research Centers
    Peoria, Arizona 85381, United States
  • HOPE Research Institute
    Phoenix, Arizona 85050, United States
  • HealthStar Research
    Hot Springs, Arkansas 71913, United States
  • Impact Clinical Trials
    Beverly Hills, California 90211, United States
  • Northern California Research
    Carmichael, California 98608, United States
  • Sierra Medical Research
    Fresno, California 93710, United States
  • Advance Clinical Research Institute
    Orange, California 92869, United States
  • Affiliated Research Institute
    San Diego, California 92108, United States
  • VA San Diego Healthcare System
    San Diego, California 92161, United States
  • Apex Research Institue
    Santa Ana, California 92705, United States
  • Chase Medical Research, LLC
    Waterbury, Connecticut 06708, United States
  • LCFP Inc.
    Fort Myers, Florida 33907, United States
  • Miami Research Associates
    Miami, Florida 33143, United States
  • Suncoast Clinical Research
    Palm Harbor, Florida 34684, United States
  • University Clinical Research
    Pembroke Pines, Florida 33024, United States
  • CSRA Partners in Health, Inc
    Augusta, Georgia 30909, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Deaconess Clinic
    Evansville, Indiana 47713, United States
  • Northwest Indiana Center for Clinical Research
    Valparaiso, Indiana 46383, United States
  • Central Kentucky Research Associates, Inc.
    Lexington, Kentucky 40509, United States
  • L-Marc
    Louisville, Kentucky 40213, United States
  • Trover Center for Clinical Studies
    Madisonville, Kentucky 42431, United States
  • Pennington Biomedical Research Center
    Baton Rouge, Louisiana 70808, United States
  • Medical Research Institute
    Slidell, Louisiana 70458, United States
  • Health Trends Research, LLC
    Baltimore, Maryland 21209, United States
  • FutureCare Studies
    Springfield, Massachusetts 01103, United States
  • Twin Cities Clinical Research
    Brooklyn Center, Minnesota 55430, United States
  • The Center for Pharmaceutical Research
    Kansas City, Missouri 64114, United States
  • Mercy Health Research
    St. Louis, Missouri 63141, United States
  • Radiant Research, Inc.
    St. Louis, Missouri 63141, United States
  • Center for Nutrition and Metabolic Diseases, Univ. of Nevada
    Reno, Nevada 89557, United States
  • Endocrinology & Diabetes Consultants
    Dover, New Hampshire 03820, United States
  • Lovelace Scientific Resources
    Albuquerque, New Mexico 87108, United States
  • Diabetes care and Information Center
    Flushing, New York 11365, United States
  • Central New York Clinical Research
    Manlius, New York 13104, United States
  • Rochester Clinical Research, Inc
    Rochester, New York 14609, United States
  • Metrolina Medical Research
    Charlotte, North Carolina 28209, United States
  • Rapid Medical Research, Inc.
    Cleveland, Ohio 44122, United States
  • Central Ohio Nutrition Center, Inc.
    Columbus, Ohio 43213, United States
  • Wells Institute for Health Awareness
    Kettering, Ohio 45429, United States
  • Your Diabetes Endocrine and Nutrition Group
    Mentor, Ohio 44060, United States
  • Mountain View Clinical Research
    Greer, South Carolina 29349, United States
  • Palmetto Medical Research
    Mt. Pleasant, South Carolina 29464, United States
  • ClinSearch
    Chattanooga, Tennessee 37404, United States
  • Clinical Research Associates, Inc.
    Nashville, Tennessee 37203, United States
  • The Cooper Institute
    Dallas, Texas 75230, United States
  • Baylor Endocrine Center
    Dallas, Texas 75246, United States
  • Diabetes Center of the Southwest
    Midland, Texas 79705, United States
  • InVisions Consultants, LLC
    San Antonio, Texas 78217, United States
  • Diabetes & Glandular Disease Research Associates, Inc.
    San Antonio, Texas 78229-4801, United States
  • Summit Research Network, Inc.
    Seattle, Washington 98104, United States
  • Northside Internal Medicine
    Spokane, Washington 99208, United States
09

References and documents

Publications

  • Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, Klassen P, Fujioka K; COR-Diabetes Study Group. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013 Dec;36(12):4022-9. doi: 10.2337/dc13-0234. Epub 2013 Oct 21. Erratum In: Diabetes Care. 2014 Feb;37(2):587. PubMed 24144653 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2014, 5 years 5 months after primary completion. A results delay was requested in Oct 2012.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2007
First posted
May 17, 2007
Start
May 2007
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Results delay requested
Oct 25, 2012
Results first posted
Nov 21, 2014
Last update
Nov 21, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00474630
Lead sponsor
Orexigen Therapeutics, Inc
Responsible party
Sponsor
First posted
May 17, 2007
Start date
May 2007
Primary completion
Jun 2009
Completion
Jun 2009
Results posted
Nov 21, 2014
Last update
Nov 21, 2014

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naltrexone

Start the discussion